New research has been announced by Ganeden Biotech, Cleveland, OH, which indicated that their probiotic strain GanedenBC30 might aid in the prevention of C. difficile-induced infection (CDI). Recently published in the journal Gut Pathogens, the study demonstrated that Bacillus coagulans GBI-30, 6086 (GanedenBC30) prevents the recurrence of CDI in mice. Additionally, the study found that the mice given GanedenBC30 when re-infected with C.diff experienced more mild symptoms and recovered faster than those mice that were not given the probiotic. Dr. David Keller, vice president of scientific operations at Ganeden Biotech and one of the study’s authors explained, “Currently antibiotics are the primary weapon in the arsenal to fight C. diff. These findings show that the probiotic GanedenBC30 may provide an alternative.” For further information: http://www.gutpathogens.com/content/4/1/13/abstract
Seong-Jae Yoo, PhD, & Gabriel Giancaspro, PhD, U.S. Pharmacopeial Convention (USP) ||March 1, 2017 USP monographs can serve as useful resources to help dietary supplement manufacturers comply with federal standards.